EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth

Karthiga Santhana Kumar, Cyrill Brunner, Matthias Schuster, Levi Luca Kopp, Alexandre Gries, Shen Yan, Simon Jurt, Kerstin Moehle, Dominique Bruns, Michael Grotzer, Oliver Zerbe, Gisbert Schneider und 1 weitere

Cellular Oncology · 2023-04 · 46 (2) · 331-356

DOI: 10.1007/s13402-022-00753-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 10.12.2022. Verfasst von Karthiga Santhana Kumar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Molecular Neuro-Oncology Research Laboratory, Children's Research Center, University Children's Hospital Zürich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Discovery. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Krebsliga Schweiz, Swiss Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Aberrant activation of the fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases drives oncogenic signaling through its proximal adaptor protein FRS2. Precise disruption of this disease-causing signal transmission in metastatic cancers could stall tumor growth and progression. The purpose of this study was to identify a small molecule ligand of FRS2 to interrupt oncogenic signal transmission from activated FGFRs.

Methods

We used pharmacophore-based computational screening to identify potential small molecule ligands of the PTB domain of FRS2, which couples FRS2 to FGFRs. We confirmed PTB domain binding of molecules identified with biophysical binding assays and validated compound activity in cell-based functional assays in vitro and in an ovarian cancer model in vivo. We used thermal proteome profiling to identify potential off-targets of the lead compound.

Results

We describe a small molecule ligand of the PTB domain of FRS2 that prevents FRS2 activation and interrupts FGFR signaling. This PTB-domain ligand displays on-target activity in cells and stalls FGFR-dependent matrix invasion in various cancer models. The small molecule ligand is detectable in the serum of mice at the effective concentration for prolonged time and reduces growth of the ovarian cancer model in vivo. Using thermal proteome profiling, we furthermore identified potential off-targets of the lead compound that will guide further compound refinement and drug development.

Conclusions

Our results illustrate a phenotype-guided drug discovery strategy that identified a novel mechanism to repress FGFR-driven invasiveness and growth in human cancers. The here identified bioactive leads targeting FGF signaling and cell dissemination provide a novel structural basis for further development as a tumor agnostic strategy to repress FGFR- and FRS2-driven tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsDrug DiscoveryAnimalsFemaleHumansMiceAdaptor Proteins, Signal TransducingLigandsMembrane ProteinsProteomeReceptors, Fibroblast Growth FactorSignal Transduction

Stichwörter der Autor:innen

Bioactive small molecule compoundCell invasionFGFRFRS2Protein–protein interaction interferenceThermal proteome profiling

Substanzen

Adaptor Proteins, Signal TransducingFRS2 protein, humanLigandsMembrane ProteinsProteomeReceptors, Fibroblast Growth Factor

Autor:innen und Institutionen

  • Pediatric Molecular Neuro-Oncology Research Laboratory, Children's Research Center, University Children's Hospital Zürich, Zurich, Switzerland.
  • Invasight, Zurich, Switzerland.
  • ETH Zurich, Department of Chemistry and Applied Biosciences, RETHINK, Zurich, Switzerland.
  • Department of Chemistry, University of Zurich, Zurich, Switzerland.
  • Department of Oncology, Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
  • ETH Singapore SEC Ltd, Singapore, Singapore.

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Krebsliga Schweiz
  • Swiss Cancer Research Foundation
  • Childhood Cancer Foundation Switzerland
  • University of Zurich

Zitieren

APA

Santhana Kumar, K., Brunner, C., Schuster, M., Kopp, L. L., Gries, A., Yan, S., Jurt, S., Moehle, K., Bruns, D., Grotzer, M., Zerbe, O., Schneider, G., & Baumgartner, M. (2023). Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth. Cellular Oncology, 46(2), 331-356. https://doi.org/10.1007/s13402-022-00753-x

Vancouver

Santhana Kumar K, Brunner C, Schuster M, Kopp LL, Gries A, Yan S, et al. Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth. Cellular Oncology. 2023;46(2):331-356. doi:10.1007/s13402-022-00753-x

BibTeX
@article{SanthanaKumar2023,
  author = {Santhana Kumar, Karthiga and Brunner, Cyrill and Schuster, Matthias and Kopp, Levi Luca and Gries, Alexandre and Yan, Shen and Jurt, Simon and Moehle, Kerstin and Bruns, Dominique and Grotzer, Michael and Zerbe, Oliver and Schneider, Gisbert and Baumgartner, Martin},
  title = {Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth},
  journal = {Cellular Oncology},
  year = {2023},
  volume = {46},
  number = {2},
  pages = {331--356},
  doi = {10.1007/s13402-022-00753-x}
}
Kostenlos starten →